Evolution of migraine vertigo in overlapping syndrome with Ménière’s disease: prognostic role of instrumental examination| ACTA Otorhinolaryngologica Italica

Abstract

Introduction. Migraine vertigo (MV) and Ménière’s disease (MD) share several signs and symptoms such as tinnitus, fullness, photophobia, phonophobia, headache and vertigo spells lasting hours.
Objective. The aim of the present study was to prospectively observe patients with MV with a sporadic audiological symptom evaluated with clinical examination, Vestibular Evoked Myogenic Potentials (VEMPs), ECochG and v-HIT.
Results. The finding of VEMP asymmetry, according to our cut-off of 33% of difference between sides, resulted in 20 cases, of which 6 had asymmetry of both c-VEMPs and o- VEMPS, all with development of fluctuating hearing during follow-up. ECochG was positive for endolymphatic hydrops in 12 patients.
Conclusions. The evolution of MV may have a variable course in which some patients may develop symptoms typical of MD. The two diseases may be contextually present at the same time configuring an overlapping syndrome, and asymmetric VEMPs might predict development of fluctuating hearing.

Introduction

Migraine vertigo (MV) and Ménière’s disease (MD) share several signs and symptoms such as tinnitus, fullness, photophobia, phonophobia, headache and vertigo spells lasting hours ^1,2. Diagnosis of MD or MV is based on anamnestic data and clinical features, making differential diagnosis very difficult ³.

In 2013, the International Headache Society published the last classification of headache diseases ICHD3-beta including the up-to-date diagnostic criteria of MV ⁴, and in 2015 the diagnostic criteria for MD are codified by the European Academy of Otology and Neurotology ⁵; both classifications are used widely to diagnose these two diseases (Tab. I).

However, in clinical practice, several patients exhibit features of both diseases. Murofushi et al. defined such patients as suffering from an overlapping syndrome of MD and MV ⁶.

The aim of the present study was to prospectively observe a series of patients with definite MV having some sporadic audiological symptom (i.e. tinnitus, fullness), but normal hearing, and followed-up with electrophysiological and clinical tests. All instrumental findings were then correlated with clinical behaviour.

Materials and methods

Among all patients with vestibular diseases who referred to our Laboratory of Acoustic Electrophysiology and Vestibology in 2016, we prospectively evaluated patients matching criteria for MV reported by ICHD3-beta and Barany Society.

All patients had focused clinical history: number of severe vertigo spells, dizziness evaluated with Dizziness Handicap Inventory Italian validated version ⁷, subjective tinnitus, fullness, subjective hearing loss and fluctuating hearing, aura symptom, triggers for headache and vertigo, anxiety, motion sickness and ascertained food intolerance.

Otomicroscopy and pure tone audiometry (PTA) testing bone and air conduction for 0.25-0.5-1-2-3-4 kHz was done in all patients. All patients also underwent tympanometry and stapedial reflexes study.

The exclusion criteria were: previous diagnosis of MD, vestibular schwannoma of VIII cranial nerve, benign paroxysmal positional vertigo, head trauma, middle ear diseases, conductive hearing loss (i.e. suspect for otosclerosis), sensorineural hearing loss, labyrinthine fistula, ototoxic drug exposure, barotrauma, middle and inner ear malformations, chronic neuropathy (i.e. diabetes, demyelinating disease, chronic renal failure) and alteration of stapedial reflex or type B and C tympanogram.

Clinical vestibular examination included: searching for spontaneous nystagmus with video-Frenzel, Dix-Hallpike test and supine roll test to exclude positional vertigo, head shaking test, head impulse test, skew test and Romberg test.

Cervical and Ocular VEMPs (c-VEMPs and o-VEMPs) were recorded in all patients with Socrates, Hedera Biomedics S.r.l. with biofeedback of muscle contraction on the monitor. Biofeedback is used to reduce the variability in case of difference in muscle contraction between sides. It is achieved through a digital LED and displayed waveform rectification, for a realistic comparison between the ipsi- and contralateral amplitudes.

Regarding o-VEMPs, the negative electrode was positioned under the eye contralateral to the acoustic stimulation side and the positive electrode a few mm under the negative one, with the ground electrode on the forehead. The patient was in a supine position and the recording started by asking patient to fix a point about 30° over the head with a distance of 1 metre. c-VEMPs were recorded with the negative electrode at the middle third of the sternocleidomastoid muscle ipsilateral to the acoustic stimuli, the positive electrode on the middle third of the clavicle and the ground electrode on the forehead; the patient was lying in a supine position with the head rotate contralateral to the acoustic stimuli and the recording was started by asking the patient to flex the head to the sternum maintaining the position during the examination. The acoustic stimuli were air conducted by earphone inserts as tone burst 500 Hz, 120 dB SPL and repeated 200 times. For each patient, the presence and repeatability of the curve and amplitude and latency of the p10-n10 complex for o-VEMPs and p13-n23 complex for c-VEMPs were evaluated; the asymmetry between two sides over 33% was considered as pathological ⁸.

The electrocochleography (ECochG) was recorded with Socrates, Hedera Biomedics S.r.l. by an extratympanic Lilly TM-Wick electrode as positive, ground electrode on the forehead and the negative electrode on the contralateral mastoid tip. The acoustic stimuli were air conducted by earphone inserts with click stimuli 120 dB SPL, alternating polarity, rhythm 5,4 msec repeated 2000 times. Both ears were tested. On the curve obtained, the SP/AP ratio was evaluated considering as pathological a result over 0.5.

The video Head Impulse Test (v-HIT) was done with Eye-See-Cam System Interacoustic. The patient was in a sitting position in front of a point to fix a 1.5 metre distance while the operator casually rotated the head to the right and to the left. The test was considered complete after 20 impulses were accepted. The vestibular-ocular reflex (VOR) gain was considered as pathological if less than 0.8 and if more than 5% of asymmetry.

The minimum follow-up considered was 24 months since first examination with scheduled revaluation at 6, 12, 18 and 24 months; the record was updated in the event that a symptom arose or worsened, or if the instrumental score had modifications. The patients were alerted to call our centre in case of sudden hearing worsening or some modification in their symptoms. Statistical analysis was done with MS Excel performing Chi-squared test and Fisher’s exact test. Our IRB approved this clinical study and the work was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).

Results

Thirty patients matched inclusion/exclusion criteria and were prospectively followed-up after first examination. The mean age was 45 years (range 18-64 years), with 24 females and 6 males. All patients complained of migraine headache: 16 patients had migraine for years (average 18 years) before vertigo spells, 10 patients had headache contextually to vertigo and in 4 subjects the vertigo spells preceded the headache (average 3 years). Eight patients had family history for vertigo, 6 for migraine alone and 6 for migraine and vertigo.

The visual aura was reported in 12 cases; photophobia was present in all cases, and 26 patients also had phonophobia. Motion sickness was present in 20 cases; anxiety was present in 26 patients and 16 patients reported documented food intolerance. The symptoms referred by patients are summarised in Table II.

All patients had normal hearing after first PTA evaluation; 10 patients complained of episodic tinnitus and 20 of transitory fullness sensation, among which 9 had both symptoms. Twenty patients reported dizziness and unsteadiness. All cases had normal gain on v-HIT examination.

In all patients it was possible to record VEMPs. All latency and amplitude values were within the normal range. The finding of VEMPs asymmetry, according to our cut-off of 33% of difference between sides, resulted in 20 cases, of which 6 with asymmetry of both c-VEMPs and o-VEMPS, 8 with asymmetric c-VEMPs alone and 6 with asymmetric o-VEMPs. Ten patients had normal and symmetric VEMPs response. The asymmetric response more than 33% resulted in a difference in amplitudes between the two sides, although the values of amplitude were in the normative range: 120 ± 50 μV for c-VEMP and 5 ± 2 μV for o-VEMP.

In 12 cases, the first ECochG showed a unilateral hydrops because the SP/AP ratio was more than 0.5. The ECochG did not show a significant relationship between fluctuating hearing and SP/AP alteration, and patients with an SP/AP ratio more than 0.5 at first examination maintained the same score at further controls. Twelve patients with altered ECochG had VEMPs amplitude and latency in the normal range, but all had both c- and o-VEMPs asymmetry > 33%, with the affected ear showing relatively low amplitude.

During follow-up, the score of instrumental examination (v-HIT, VEMPs and ECochG) of all patients was repeatable and without significant modification. In 16 patients a fluctuation of sensorineural hearing level was documented at PTA and in 4 cases among these the sensorineural hearing loss become stable at an average of 40 dB. In 18 patients re-evaluated for acute vertigo, the spell did not have a noticeable nystagmus at the moment of the visit and repeat instrumental examination did not show any changes.

Statistical analysis was carried out to search for a relationship between fluctuations of hearing and clinical or instrumental features. The presence of asymmetry of both o-VEMPS and c-VEMPs was significantly related to fluctuating hearing (p < 0.05). The data are summarised in Table III. Fluctuating hearing was found in the same side of low amplitude of VEMPs.

Discussion

This study focused on patients suffering for MV meeting ICDH3-beta criteria. This clinical entity, like migraine headache, is predominant in women (24/30 in our series) in the 3rd and 4th decade of life. Family predisposition is present in about half of MV patients of our experience, and a possible autosomal dominant genetic transmission may be responsible ⁹.

Photophobia and phonophobia are two symptoms frequently described by MV patients, as in our series where they were present in about 90% of cases ¹⁰. Motion sickness was reported as a frequent symptom in all MV patients by Pagnini et al. ¹¹; in our findings, 66% of patients complained of this symptom.

The study of vestibular-oculomotor reflex with v-HIT in our series was normal in all subjects with MV, including those who developed fluctuation of hearing during follow-up. v-HIT applied to MV patients did not show a clinical importance as reported by ElSherif et al. who compared healthy subjects and MV patients and found no alterations in gain or other parameters, underscoring the normality of vestibular-ocular reflex in MV patients ¹².

Often MV patients complain of hearing issues like fullness, tinnitus and even hearing loss. These symptoms associated with migraine symptoms could imply a challenging differential diagnosis with MD ¹. For these reasons, an overlapping syndrome was hypothesised in patients that match both clinical classifications based on referred symptoms ^6,10. Our prospective evaluation of MV patients highlighted that asymmetry of both VEMPs could be a predictor of potential development of an overlapping syndrome with MD.

Several studies have attempted to find a gold standard test that could differentiate VM, MD and non-vestibular migraine ^13-17. The calculation of the SP/AP ratio through electrocochleography (EcochG) has often been reported to be an objective index of endolymphatic hydrops in MD, even though it is limited by low sensitivity and its reliability is strictly dependent on the EcochG technique used, type of stimulus given and stage of MD. In contrast, scarce data are available relative to the use of EcochG in patients with VM. As in the present series of patients, Vitkovic et al. studied 523 patients and found no difference in EcochG test results between VM and MD patients ¹³. Lotfi et al. also observed no relevant EcochG differences between patients with VM and healthy subjects in a case series of 20 patients ¹⁴. In contrast, Yollu et al. reported higher SP/AP ratios among patients with VM with respect to migraineurs without complaints of vertigo ¹⁶.

As is known, c-VEMPs is the first instrumental test that shows some alteration in MD due to early involvement of the saccule by endolymphatic hydrops with high sensitivity of the macula to low frequency ^17,18.

In patients with MV, the results of c-VEMPs are conflicting without unique interpretations. Boldingh et al. reported 43% of their cases had absent potential ¹⁹. Liao and Young evaluated 20 patients with basilar artery migraine with dizziness and c-VEMPs were absent in 35% of cases ²⁰.

Zaleski et al. found no difference in c-VEMPs between MV patients and controls, but they reported the absence of o-VEMPs in 28% of cases and low amplitude or asymmetry in large majority of MV patients ²¹.

However, alteration of o-VEMPs are variously described in the literature with contradictory results. Makowiec et al. reported that 51 patients among 83 with MV had asymmetry of o-VEMPs, while Zuniga et al. found no difference in amplitude of o-VEMPs between MV patients and normal subjects ^22,23.

Hearing in MV patients is in line with general population; on the contrary, in MD hearing loss is a parameter required to achieve a diagnosis ⁴. The fluctuating hearing in some of our patients during follow-up could indicate a possible correlation between both c-VEMPs and o-VEMPs findings and clinical behaviour of MV over time. The documented fluctuation of hearing associated with vertigo spells lasting hours, which we recorded in some MV patients during follow-up, is more typical for MD compared to MV. In our opinion, some MV patients may develop MD as an evolution of a latent inner ear disease, which for a period of time manifests only with migraine-associated vertigo. Another possible explication could be that MD is latent for a phase of life and manifests with MV-like symptomatology. According to findings of Makowiec et al. ²³, a patient with MV is likely to have abnormal o-VEMPs and normal c-VEMPs and most patients with MD have alterations of c-VEMPs. Although our data are limited by the small number of cases observed, in our series it was noted that a patient with MV symptoms with both o-VEMPs and c-VEMPs asymmetry already has or will develop MD during their lifetime ¹⁵.

Conclusions

The evolution of MV during the life of patients can have variable progression in which some may develop symptoms typical of MD. The two diseases can be contextually present at the same time, configuring an overlapping syndrome. This condition is an expression of some alterations in the inner ear. The instrumental evaluation of inner ear functions provides information about the status of the system and the asymmetry of both c- and o-VEMPs, although as observed in our small series, seems to be related to a high risk of developing fluctuating hearing during the course of MV. Further study on a larger number of patients could help to better explain the link between MV and MD.

Figures and tables

References

1. Neff BA, Staab JP, Eggers SD. Auditory and vestibular symptoms and chronic subjective dizziness in patients with Meniere’s disease, vestibular migraine, and Ménière’s disease with concomitant vestibular migraine. Otol Neurotol. 2012; 33:1235-1244. DOI
2. Teggi R, Battista RA, Di Berardino F. Evaluation of a large cohort of adult patients with Ménière’s disease: bedside and clinical history. Acta Otorhinolaryngol Ital. 2020; 40:444-449. DOI
3. Radtke A, Lempert T, Gresty MA. Migraine and Ménière’s disease: is there a link?. Neurology. 2002; 59:1700-1704. DOI
4. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33:629-808. DOI
5. Lopez-Escamez JA, Carey J, Chung WH. Diagnostic criteria for Ménière’s disease. J Vestib Res. 2015; 25:1-7. DOI
6. Murofushi T, Tsubota M, Kitao K. Simultaneous presentation of definite vestibular migraine and definite Ménière’s disease: overlapping syndrome of two diseases. Front Neurol. 2018; 9:749. DOI
7. Nola G, Mostardini C, Salvi C. Validity of Italian adaptation of the Dizziness Handicap Inventory (DHI) and evaluation of the quality of life in patients with acute dizziness. Acta Otorhinolaryngol Ital. 2010; 30:190-197.
8. Dispenza F, Mazzucco W, Mazzola S. Observational study on risk factors determining residual dizziness after successful benign paroxysmal positional vertigo treatment: the role of subclinical BPPV. Acta Otorhinolaryngologica Ital. 2019; 39:347-352. DOI
9. Bahmad F, DePalma SR, Merchant SN. Locus for familial migrainous vertigo disease maps to chromosome 5q35. Ann Otol Rhinol Laryngol. 2009; 118:670-676. DOI
10. Lopez-Escamez JA, Dlugaiczyk J, Jacobs J. Accompanying symptoms overlap during attacks in Ménière’s disease and vestibular migraine. Front Neurol. 2014; 5:265. DOI
11. Pagnini P, Verrecchia L, Giannoni B. Migraine-related vertigo (MV). Acta Otorhinolaryngol Ital. 2003; 23:19-27.
12. ElSherif M, Reda MI, Saadallah H. Video head impulse test (vHIT) in migraine dizziness. J Otol. 2018; 13:65-67. DOI
13. Vitkovic J, Paine M, Rance G. Neuro-otological findings in patients with migraine- and nonmigraine-related dizziness. Audiol Neurootol. 2008; 13:113-122. DOI
14. Lotfi Y, Mardani N, Rezazade N. Vestibular function in patients with vestibular migraine. Aud Vest Res. 2016; 25:166-174.
15. Martines F, Dispenza F, Montalbano C. Comparison of electrocochleography and video head impulse test findings in vestibular migraine and Ménière disease: a preliminary study. Int Adv Otol. 2020; 16:183-189. DOI
16. Yollu U, Uluduz DU, Yilmaz M. Vestibular migraine screening in a migraine-diagnosed patient population, and assessment of vestibulocochlear function. Clin Otolaryngol. 2017; 42:225-233. DOI
17. Maxwell R, Jerin C, Gurkov R. Utilisation of multi-frequency VEMPs improves diagnostic accuracy for Ménière’s disease. Eur Arch Otorhinolaryngol. 2017; 274:85-93. DOI
18. Scarpa A, Gioacchini FM, Cassandro E. Clinical application of cVEMPs and oVEMPs in patients affected by Ménière’s disease, vestibular neuritis and benign paroxysmal positional vertigo: a systematic review. Acta Otorhinolaryngol Ital. 2019; 39:298-307. DOI
19. Boldingh MI, Ljostad U, Mygland A. Vestibular sensitivity in vestibular migraine: VEMPs and motion sickness susceptibility. Cephalalgia. 2011; 31:1211-1219. DOI
20. Liao LJ, Young YH. Vestibular evoked myogenic potentials in basilar artery migraine. Laryngoscope. 2004; 114:1305-1309. DOI
21. Zaleski A, Bogle J, Starling A. Vestibular evoked myogenic potentials in patients with vestibular migraine. Otol Neurotol. 2015; 36:295-302. DOI
22. Zuniga MG, Janky KL, Schubert MC. Can vestibular-evoked myogenic potentials help differentiate Ménière disease from vestibular migraine?. Otolaryngol Head Neck Surg. 2012; 146:788-796. DOI
23. Makowiec KF, Piker EG, Jacobson GP. Ocular and cervical vestibular evoked myogenic potentials in patients with vestibular migraine. Otol Neurotol. 2018; 39:e561-e567. DOI